CONCORDBIO.NS
CONCORDBIO.NS
INE338H01029
CONCORD BIOTECH LIMITED
Loading chart...

Company Profile

Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Related stocks

ONESOURCE.NS
ONESOURCE.NS • India
ONESOURCE SPECL PHARMA L
1,461.3 INR
1.73B USD 1Y -22.7%
2595.HK
2595.HK • China
GENFLEET-B
28.6 HKD
1.4B USD 1Y -21%
1952.HK
1952.HK • China
EVEREST MED
29.6 HKD
1.33B USD 1Y -47.1%
000403.SZ
000403.SZ • China
PLBIO
9.96 CNY
1.42B USD 1Y -39.1%
SUPRIYA.NS
SUPRIYA.NS • India
SUPRIYA LIFESCIENCE LTD
847.65 INR
704.91M USD 1Y +17.7%
688382.SS
688382.SS • China
INVENTISBIO CO LTD
17.26 CNY
1.5B USD 1Y -42.5%
688739.SS
688739.SS • China
LIAONING CHENGDA BIOTECHNOLOGY
21.2 CNY
1.32B USD 1Y -21.9%
ANTHEM.NS
ANTHEM.NS • India
ANTHEM BIOSCIENCES LTD
862.3 INR
5B USD 1Y +13.1%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
43.4% p.a.
Max Drawdown (3Y)
-61.0%
Sharpe Ratio (3Y)
0.08
Beta Factor
0.37
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 46.9 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende